Dr. Reshma Kewalramani, M.D. FASN is a distinguished medical doctor and leader in biotech, who is at the helm of Vertex Pharmaceuticals as CEO and President.
Dr. Kewalramani transitioned to the role of CEO and President on April 1, 2020. A highly experienced medical doctor, clinician, researcher and nephrologist, she is well equipped to lead Vertex into its next stage of growth.
She previously held the positions of Executive Vice President, Chief Medical Officer and Senior Vice President. During her time at Vertex, the company has pioneered ground-breaking medical treatments for cystic fibrosis, namely SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, bringing these transformative new therapies to the majority of CF patients around the world.
Formerly, Dr. Kewalramani spent more than 12 years at Amgen in several senior roles, notably as Vice President, Head US Medical Organization. During this time, Dr. Kewalramani expanded Amgen’s Research and Development unit and established the US Medical Organization which oversaw molecular responsibilities.
A passionate doctor, teacher, mentor, philanthropist and STEM advocate, Dr. Kewalramani is active in her community. Amongst many of her other roles and responsibilities, she is a Fellow of the American Society of Nephrology, a board member of the Biomedical Science Careers Program, a member of the Dean’s Advisory Committee at Boston University Medical School, and a board member of RIZE Massachusetts.
Dr. Kewalramani completed her internship and residency at several Mass General Brigham medical centers, including as Resident Physician at Massachusetts General Hospital.
Throughout her notable career, she has earned several accolades, most recently as a leading CEO of a Fortune 500 biotech company and as an International Institute of New England Golden Door Award Honoree.
Dr. Kewalramani is an alumnus of Harvard Business School and holds a Summa Cum Laude medical degree from Boston University School of Medicine.
